ZNF569 is a zinc finger protein containing KRAB and zinc finger motifs that functions as a transcriptional repressor 1. The protein is expressed across most human adult and embryonic tissues, with elevated levels in heart and skeletal muscles 1. ZNF569 suppresses transcriptional activity through its repression domains and inhibits MAPK signaling pathway components including SRE and AP-1 1. Beyond its transcriptional regulatory role, ZNF569 has emerged as a clinically relevant biomarker. Its promoter methylation patterns distinguish Barrett's esophagus from normal squamous esophagus, with hypermethylation associated with premalignant disease 23. In esophageal cancer, ZNF569 methylation accurately detects malignancy prior to and following neoadjuvant chemoradiation, particularly in adenocarcinoma, with potential utility in liquid biopsies 4. ZNF569 methylation also functions as a biomarker for gastric adenocarcinoma detection in both tissue and plasma samples, where a three-marker panel including ZNF569 achieved 86% sensitivity at 95% specificity 5. Additionally, ZNF569 protein levels modulate cellular sensitivity to paclitaxel chemotherapy 6, suggesting roles in drug response mechanisms.